Median survival was 24.6 months, according to data from the 123 myeloma patients who took Elrexfio with the first group in MagnetisMM-3.| Myeloma Research News
The CAR T-cell therapy Carvykti controlled disease activity in most myeloma patients who hadn't fully responded to standard cell transplant.| Myeloma Research News